MAVS antibody

Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
MAVS antibody
category
Primary Antibodies
provider
FineTest
reference
FNab05032
tested applications
ELISA, WB, IF, IP, IHC

Description

Required for innate immune defense against viruses. Acts downstream of DDX58/RIG-I and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFN-beta and RANTES(CCL5). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state. Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response. May activate the same pathways following detection of extracellular dsRNA by TLR3. May protect cells from apoptosis.It can undergoe phosphorylation on multiple sites and ubiquitination, which may together cause the molecular weight migrate to about 70 kDa despite the predicated 57 kDa.

Documents del producto

Instrucciones
Descargar
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
mitochondrial antiviral signaling protein (MAVS)
Host
Rabbit
Reactivity
Human, Mouse
Recommended Dilution
WB: 1:1000-1:4000; IP: 1:500-1:2000; IHC: 1:100-1:500; IF: 1:10-1:100
Clonality
polyclonal
Conjugation
Unconjugated
Isotype
IgG
Observed MW
70 kDa
Purity
≥95% as determined by SDS-PAGE
Purification
Immunogen affinity purified
Size 1
100µg
Form
liquid
Tested Applications
ELISA, WB, IF, IP, IHC
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
UniProt ID
Q7Z434
Alias
Mitochondrial antiviral-signaling protein (MAVS),CARD adapter inducing interferon beta (Cardif),Interferon beta promoter stimulator protein 1 (IPS-1),Putative NF-kappa-B-activating protein 031N,Virus-induced-signaling adapter (VISA),MAVS,IPS1,KIAA1271,VISA
Background
Antibody anti-MAVS
Status
RUO
Note
Mol. Weight 70 kDa

Descripción

Related Products

FNab05032

MAVS antibody

Required for innate immune defense against viruses. Acts downstream of DDX58/RIG-I and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFN-beta and RANTES(CCL5). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state. Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response. May activate the same pathways following detection of extracellular dsRNA by TLR3. May protect cells from apoptosis.It can undergoe phosphorylation on multiple sites and ubiquitination, which may together cause the molecular weight migrate to about 70 kDa despite the predicated 57 kDa.

Ver Producto
FNab10248

MAVS antibody

Required for innate immune defense against viruses. Acts downstream of DDX58/RIG-I and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFN-beta and RANTES(CCL5). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state. Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response. May activate the same pathways following detection of extracellular dsRNA by TLR3. May protect cells from apoptosis.It can undergoe phosphorylation on multiple sites and ubiquitination, which may together cause the molecular weight migrate to about 70 kDa despite the predicated 57 kDa.

Ver Producto
P0236

Recombinant Human MAVS

Ver Producto